Rapid Dose Therapeutics Corp. (RDTCF)
| Previous Close | 0.0080 |
| Open | 0.0080 |
| Bid | 0.0120 x 0 |
| Ask | 0.2000 x 0 |
| Day's Range | 0.0080 - 0.0080 |
| 52 Week Range | 0.0021 - 0.3900 |
| Volume | |
| Avg. Volume | 2,781 |
| Market Cap | 20.814M |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Oct 28, 2024 - Nov 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileRapid Dose Announces Payment in Shares for Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - October 1, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on September 30, 2024 under the terms of the Financing and the Notes, and expects to issue the Common ...
NewsfileRapid Dose Provides Update on Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - September 16, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated August 7, 2024, regarding a proposed equity private placement financing (the "Financing"), the Company has received an extension from the Canadian Securities Exchange allowing it to close the Financing on or before October 29, 2024. This previously announced Financing contemplates an aggregate of up to $6,000,000 .
NewsfileRapid Dose Announces Closing of First Tranche of Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - July 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the "Financing") for aggregate gross proceeds of $309,000.The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and general working capital requirements.The Financing allowed for a maximum of $6,000,
